Fidelity Advisor Health Care Fund Class C
FHCCX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Fidelity Advisor Series VII MA United States of America
- IPO Date
- Sep 30, 1996
- CIK
- 0000315700
- Website
- fundresearch.fidelity.com
- Similar Companies
- Business
- Fidelity Advisor Health Care Fund Class C (FHCCX) is an actively managed open-end mutual fund offered by Fidelity Investments that seeks capital appreciation by investing primarily in securities of companies engaged in health care-related industries. The fund allocates assets across pharmaceuticals; biotechnology; health care equipment and supplies; life sciences tools and services; health care providers and services; and health care technology, with a flexible approach that may include domestic and foreign issuers, common stocks, preferred stocks, convertible securities, and derivatives such as futures and options for hedging or efficient portfolio management. It targets companies of any market capitalization, emphasizing those demonstrating strong fundamentals, growth potential, and attractive valuations within the health care sector, serving individual investors, financial advisors, retirement plans, and institutional clients seeking sector-specific exposure. Fidelity Investments, the fund's sponsor and manager, founded in 1946 and headquartered in Boston, Massachusetts, operates globally with major offices in the United States, Europe, Asia-Pacific, and Latin America; the fund benefits from Fidelity's extensive research capabilities, including proprietary quantitative models and a dedicated health care equity team led by portfolio manager Edward Yoon since 2019. Geographically, the fund invests worldwide, with a core focus on U.S.-listed securities but flexibility for international holdings representing up to 20% of assets in developed and emerging markets. In recent developments, the fund maintained stable performance amid market volatility, with no major portfolio restructurings or class-specific changes reported in 2024-2025; Fidelity Investments announced enhancements to its advisor platform in late 2024, improving access to sector funds like FHCCX through streamlined reporting and ESG integration options, while the broader health care sector saw strategic shifts such as Fidelity's increased emphasis on precision medicine investments following partnerships with biotech innovators. No acquisitions, funding rounds, or name changes affected FHCCX directly in the past 1-2 years, though Fidelity completed the integration of certain acquired asset management capabilities to bolster active equity strategies. The fund remains part of Fidelity's Advisor class lineup, distinguished by its Class C share structure featuring a 1% contingent deferred sales charge and higher expense ratio approximating 1.85% as of mid-2025.